Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 4.2%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded down 4.2% during trading on Tuesday . The stock traded as low as $22.65 and last traded at $22.67. 54,551 shares were traded during trading, a decline of 89% from the average session volume of 516,126 shares. The stock had previously closed at $23.66.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $64.86.

Arcturus Therapeutics Stock Performance

The company’s fifty day moving average price is $30.12 and its 200-day moving average price is $32.62. The stock has a market cap of $570.92 million, a P/E ratio of -5.75 and a beta of 2.65.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The company had revenue of $38.01 million during the quarter, compared to analyst estimates of $22.12 million. Analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 26,000 shares of Arcturus Therapeutics stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its position in Arcturus Therapeutics by 7.7% during the 4th quarter. ARK Investment Management LLC now owns 2,047,687 shares of the biotechnology company’s stock valued at $64,564,000 after purchasing an additional 146,141 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Arcturus Therapeutics by 11.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,088,930 shares of the biotechnology company’s stock worth $34,336,000 after buying an additional 115,087 shares during the last quarter. FMR LLC grew its position in shares of Arcturus Therapeutics by 8.6% in the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock worth $24,024,000 after buying an additional 74,081 shares during the last quarter. Granahan Investment Management LLC grew its position in shares of Arcturus Therapeutics by 12.9% in the 4th quarter. Granahan Investment Management LLC now owns 450,366 shares of the biotechnology company’s stock worth $14,200,000 after buying an additional 51,504 shares during the last quarter. Finally, Great Lakes Advisors LLC purchased a new position in shares of Arcturus Therapeutics in the 4th quarter worth approximately $6,531,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.